{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-25-000092","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.470970+00:00","generated_at":"2026-05-16T20:29:49.356633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Instil Bio reports Q3 net loss $2.01/share; first patient dosed in Phase 1 trial of AXN-2510","bullets":["Cash position $83.4M as of Sept 30, 2025, down from $115.1M at Dec 31, 2024; expects runway beyond 2026.","First patient dosed in Phase 1 trial of AXN-2510/IMM2510 monotherapy in advanced solid tumors in October 2025.","R&D expenses $9.1M in Q3 2025 vs $0.6M in Q3 2024; reflecting increased clinical activity.","Net loss per share (GAAP) $2.01 in Q3 2025 vs $3.54 in Q3 2024; non-GAAP net loss $1.75 vs $2.55."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-25-000092","json":"https://secwatch.observer/filing/0001789769-25-000092.json","markdown":"https://secwatch.observer/filing/0001789769-25-000092.md","text":"https://secwatch.observer/filing/0001789769-25-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/0001789769-25-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/til-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:29:49.356633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}